-
Je něco špatně v tomto záznamu ?
Co-milling of glass forming ability class III drugs: Comparing the impact of low and high glass transition temperatures
N. Pätzmann, J. Beránek, BT. Griffin, M. Kuentz, PJ. O'Dwyer
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, srovnávací studie
- MeSH
- Aspirin chemie analogy a deriváty MeSH
- fenofibrát * chemie MeSH
- pomocné látky chemie MeSH
- příprava léků metody MeSH
- rozpustnost MeSH
- sklo * chemie MeSH
- thalidomid analogy a deriváty MeSH
- tranzitní teplota MeSH
- uvolňování léčiv MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
With an increasing focus on sustainable technologies in the pharmaceutical industry, milling provides a solvent-free approach to improve drug dissolution. Milling of drugs with an excipient offers additional opportunities to achieve supersaturation kinetics. Therefore, this work aims to present insights of co-milling fenofibrate and apremilast, two good glass formers with low and high glass transition temperatures (Tgs) respectively. Drugs were co-milled with croscarmellose sodium for various process durations followed by thermal analysis, investigation of crystallinity, surface area and dissolution. The dissolution enhancement of the low-Tg glass former fenofibrate highly correlated with the process-induced increase in surface area of co-milled systems (R2 = 0.96). In contrast, the high-Tg glass former apremilast lost its crystalline order gradually after ≥ 10 min of co-milling, and favourable supersaturation kinetics during biorelevant dissolution testing were observed. Interestingly, the melting point of co-milled apremilast decreased and linearly correlated with the highest measured drug concentration (cmax) during in vitro dissolution (onset temperature R2 = 0.98; peak temperature R2 = 0.96). The melting point depression remained stable after 90 days for apremilast, whereas fenofibrate co-milled for 20 min or more showed an increase in melting point upon storage. This study demonstrated that co-milling with croscarmellose sodium is ideally suited to good glass formers with a high Tg. The melting point depression is thereby proposed as an easily accessible critical quality attribute to estimate likely dissolution performance of drugs in dry co-milled formulations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015518
- 003
- CZ-PrNML
- 005
- 20250731091035.0
- 007
- ta
- 008
- 250708e20250324ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2025.107081 $2 doi
- 035 __
- $a (PubMed)40139572
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Pätzmann, Nicolas $u School of Pharmacy, University College Cork, Cork, Ireland; Department Preformulation and Biopharmacy, Zentiva, k.s., Prague, Czechia
- 245 10
- $a Co-milling of glass forming ability class III drugs: Comparing the impact of low and high glass transition temperatures / $c N. Pätzmann, J. Beránek, BT. Griffin, M. Kuentz, PJ. O'Dwyer
- 520 9_
- $a With an increasing focus on sustainable technologies in the pharmaceutical industry, milling provides a solvent-free approach to improve drug dissolution. Milling of drugs with an excipient offers additional opportunities to achieve supersaturation kinetics. Therefore, this work aims to present insights of co-milling fenofibrate and apremilast, two good glass formers with low and high glass transition temperatures (Tgs) respectively. Drugs were co-milled with croscarmellose sodium for various process durations followed by thermal analysis, investigation of crystallinity, surface area and dissolution. The dissolution enhancement of the low-Tg glass former fenofibrate highly correlated with the process-induced increase in surface area of co-milled systems (R2 = 0.96). In contrast, the high-Tg glass former apremilast lost its crystalline order gradually after ≥ 10 min of co-milling, and favourable supersaturation kinetics during biorelevant dissolution testing were observed. Interestingly, the melting point of co-milled apremilast decreased and linearly correlated with the highest measured drug concentration (cmax) during in vitro dissolution (onset temperature R2 = 0.98; peak temperature R2 = 0.96). The melting point depression remained stable after 90 days for apremilast, whereas fenofibrate co-milled for 20 min or more showed an increase in melting point upon storage. This study demonstrated that co-milling with croscarmellose sodium is ideally suited to good glass formers with a high Tg. The melting point depression is thereby proposed as an easily accessible critical quality attribute to estimate likely dissolution performance of drugs in dry co-milled formulations.
- 650 12
- $a fenofibrát $x chemie $7 D011345
- 650 _2
- $a tranzitní teplota $7 D044366
- 650 12
- $a sklo $x chemie $7 D005898
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a pomocné látky $x chemie $7 D005079
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a Aspirin $x chemie $x analogy a deriváty $7 D001241
- 650 _2
- $a thalidomid $x analogy a deriváty $7 D013792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Beránek, Josef $u Department Preformulation and Biopharmacy, Zentiva, k.s., Prague, Czechia
- 700 1_
- $a Griffin, Brendan T $u School of Pharmacy, University College Cork, Cork, Ireland
- 700 1_
- $a Kuentz, Martin $u Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland
- 700 1_
- $a O'Dwyer, Patrick J $u School of Pharmacy, University College Cork, Cork, Ireland. Electronic address: patrick.odwyer@ucc.ie
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences $x 1879-0720 $g Roč. 209 (20250324), s. 107081
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40139572 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091030 $b ABA008
- 999 __
- $a ok $b bmc $g 2366390 $s 1252643
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 209 $c - $d 107081 $e 20250324 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur J Pharm Sci $x MED00001639
- LZP __
- $a Pubmed-20250708